My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 387

    1.

    Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.

    Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA.

    Diabetes Care. 2006 May;29(5):1016-23.PMID: 16644631 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

    Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

    Clin Ther. 2005 Aug;27(8):1181-95.PMID: 16199244 [PubMed - indexed for MEDLINE]Related articles

    3.

    One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

    Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group.

    Diabetes Care. 2004 Jan;27(1):141-7.PMID: 14693980 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.

    Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP.

    Curr Med Res Opin. 2006 Dec;22(12):2575-90.PMID: 17166340 [PubMed - indexed for MEDLINE]Related articles

    5.

    Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

    Saad MF, Greco S, Osei K, Lewin AJ, Edwards C, Nunez M, Reinhardt RR; Ragaglitazar Dose-Ranging Study Group.

    Diabetes Care. 2004 Jun;27(6):1324-9.PMID: 15161783 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.

    Umpierrez G, Issa M, Vlajnic A.

    Curr Med Res Opin. 2006 Apr;22(4):751-9.PMID: 16684436 [PubMed - indexed for MEDLINE]Related articles

    7.

    Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride.

    Rubin CJ, Ledeine JM, Fiedorek FT.

    Diab Vasc Dis Res. 2008 Sep;5(3):168-76.PMID: 18777489 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

    Nissen SE, Wolski K, Topol EJ.

    JAMA. 2005 Nov 23;294(20):2581-6. Epub 2005 Oct 20.PMID: 16239637 [PubMed - indexed for MEDLINE]Related articles

    9.

    Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.

    Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL.

    Clin Ther. 2000 Dec;22(12):1395-409.PMID: 11192132 [PubMed - indexed for MEDLINE]Related articles

    10.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    11.

    Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.

    Betteridge DJ, Vergès B.

    Diabetologia. 2005 Dec;48(12):2477-81. Epub 2005 Nov 10.PMID: 16283239 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    13.

    Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

    Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.

    Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M.

    Lancet. 2009 Jul 11;374(9684):126-35. Epub 2009 Jun 8.PMID: 19515415 [PubMed - indexed for MEDLINE]Related articles

    15.

    Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.

    Dailey GE 3rd, Mohideen P, Fiedorek FT.

    Clin Ther. 2002 Sep;24(9):1426-38.PMID: 12380634 [PubMed - indexed for MEDLINE]Related articles

    16.

    Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.

    Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M.

    Diabetologia. 2005 Jun;48(6):1093-104. Epub 2005 May 12.PMID: 15889234 [PubMed - indexed for MEDLINE]Related articles

    17.

    Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

    J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

    18.

    Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.

    Clin Ther. 2004 May;26(5):744-54.PMID: 15220018 [PubMed - indexed for MEDLINE]Related articles

    19.

    Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.

    Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet [corrected] Study Group.

    J Clin Endocrinol Metab. 2004 Dec;89(12):6068-76. Erratum in: J Clin Endocrinol Metab. 2005 Feb;90(2):746. PMID: 15579760 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials.

    Rajagopalan R, Iyer S, Khan M.

    Curr Med Res Opin. 2005 Jan;21(1):163-72.PMID: 15881488 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity